期刊
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
卷 1, 期 3, 页码 264-271出版社
WILEY
DOI: 10.1002/wnan.6
关键词
-
资金
- National Cancer Institute
- National Institutes of Health [N01-00-12400]
Nanotechnology offers many potential benefits to cancer research through passive and active targeting, increased solubility/bioavailablility, and novel therapies. However, preclinical characterization of nanoparticles is complicated by the variety of materials, their unique surface properties, reactivity, and the task of tracking the individual components of multicomponent, multifunctional nanoparticle therapeutics in in vivo studies. There are also regulatory considerations and scale-up challenges that must be addressed. Despite these hurdles, cancer research has seen appreciable improvements in efficacy and quite a decrease in the toxicity of chemotherapeutics because of 'nanotech' formulations, and several engineered nanoparticle clinical trials are well underway. This article reviews some of the challenges and benefits of nanomedicine for cancer therapeutics and diagnostics. (C) 2009 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2009 1 264-271
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据